BioNTech to Pay CureVac, GSK $740M Plus Royalties to Settle mRNA Patent Disputes
The deal helps move BioNTech’s proposed acquisition of CureVac closer to completion. With the settlement, GSK said it will tender the CureVac shares it owns in support of the $1.25 billion acquisition. The post BioNTech to Pay CureVac, GSK $740M Plus Royalties to Settle mRNA Patent Disputes appeared first on MedCity News.
